Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over Study of Ruxolitinib With or Without Panobinostat
NCT02386800Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 4, open-label, single-arm trial of ruxolitinib in primary myelofibrosis (PMF), polycythemia vera (PV), graft-versus-host disease (GVHD) and 2 more, sponsored by Novartis. Primary endpoint: Incidence and severity of Adverse Events and Serious Adverse Events at 12 years. Started Mar 2015; status: active, not recruiting.
02
Drugs
03
Conditions
primary myelofibrosis (PMF)polycythemia vera (PV)graft-versus-host disease (GVHD)acute myeloid leukemia (AML)thalassemia
Beyond the preview
Go deeper on NCT02386800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386800.